This article is based on the work originally performed on Jolene Edgar’s Substack. The aesthetics are not filtered.
American Association of Plastic Surgeons (ASP) Annual Trend Spotting Report Arrived and plotted the popularity of plastic surgery and non-invasive procedures. Every year, we do not fail to analyse important changes in aesthetics and provide juicy surprises.
The newly announced 2024 installments had some highlights. There was a demand for almost stable cosmetic interventions across surgical and minimally invasive categories, without large spikes. Although face lifts and associated glows, such as brow lifts and lip lifts, were dominated on social media, the most popular plastic surgery procedure in OR was actually butt and thigh lifts, and interestingly, cheek implants each recorded a 3% increase from the previous year. In the non-surgical field, neuromodulators (such as Botox, Zeomin, and Dysport) and hyaluronic acid fillers (such as Restaurants and Juvedam) each claimed the top two spots. Second, people were getting more skin resurfacing treatments (skin, laser, microdermabrasion). This has increased by 6% since 2023.
But what caught my eye was a much larger number. % change 2024 vs 2023 Column: Negative 40%. This was data equivalent to free falls and was attached to the number of non-invasive fat reduction procedures (such as Cool Sculpting, Banksch, Keebera, etc.) implemented by plastic surgeons year-over-year. They fell from 745,967 in 2023 to 447,581 in 2024.
According to some doctors, the most surprising thing about drop-off is the fact that it took a very long time to occur. When I posted on Instagram about the rapid decline, the plastic surgeon responded with comments like, “Finally!” And “Thank God!” These treatment achievements (some people are well known for complications as well as the results, consider the factors behind the Ozempic phenomenon. Perhaps we can see why these methods for freezing or heating or killing fat cells have begun to fall from favor.
Bob BassMD is a board-certified plastic surgeon in Houston, and is the presidential election for ASPS, attributed to both what he calls “sudden decline,” and what he sees as the GLP-1 boom and what is considered a modern patient back mentality.
“The increase in GLP-1 drugs for weight loss has fundamentally changed the landscape,” says Dr. Basu. By targeting visceral fat – “Deep intraperitoneal fat [cushioning our organs] These drugs have completely transformative results. And since those who lose a significant amount of weight usually leave loose, droopy skin, they can shift their focus to tightening the skin with both surgery and tack, minimizing the modality that will not strain the skin.
Source: Allure – www.allure.com
